Details for Patent: 8,415,362

Which drugs does patent 8,415,362 protect, and when does it expire?

Patent 8,415,362 protects OPZELURA, JAKAFI XR, and JAKAFI, and is included in three NDAs.

Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and fifty-seven patent family members in thirty-five countries.

Summary for Patent: 8,415,362

Title:	Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines of Formula I: that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri
Assignee:	Incyte Corp , Incyte Holdings Corp
Application Number:	US12/138,082
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,415,362
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,415,362

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-001	May 1, 2026		RX	Yes	No					Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-002	May 1, 2026		RX	Yes	No					Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-003	May 1, 2026		RX	Yes	No					Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-004	May 1, 2026		RX	Yes	No					Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-005	May 1, 2026		RX	Yes	Yes					Y

International Family Members for US Patent 8,415,362

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1966202		C300574	Netherlands
European Patent Office	1966202		PA2013002	Lithuania
European Patent Office	1966202		CA 2013 00005	Denmark
European Patent Office	1966202		C20130003 00072	Estonia
European Patent Office	1966202		1390005-5	Sweden
European Patent Office	1966202		92137	Luxembourg